Edgewise Therapeutics, Inc. Finance Lease, Right-of-Use Asset, Amortization
Edgewise Therapeutics, Inc. (EWTX) reported Finance Lease, Right-of-Use Asset, Amortization of $109.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-06
- Edgewise Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $56.00K, a 27.27% increase year-over-year.
- Edgewise Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $53.00K, a 29.27% increase year-over-year.
- Edgewise Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $50.00K, a 3.85% decline year-over-year.
- Edgewise Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $47.00K, a 25.40% decline year-over-year.
- Edgewise Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2025 was $182.00K, a 17.65% decline from fiscal 2024.
- Edgewise Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2024 was $221.00K, a 22.10% increase from fiscal 2023.
- Edgewise Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2023 was $181.00K, a 6.47% increase from fiscal 2022.
- Edgewise Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2022 was $170.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $56.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $109.00K 10-Q · filed 2026-08-06 | $159.00K derived: sum of 3 quarters · filed 2026-08-06 | $206.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $53.00K 10-Q · filed 2026-05-07 | $103.00K derived: sum of 2 quarters · filed 2026-05-07 | $150.00K derived: sum of 3 quarters · filed 2026-05-07 | $194.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $97.00K derived: sum of 2 quarters · filed 2026-02-26 | $141.00K derived: sum of 3 quarters · filed 2026-08-06 | $182.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $91.00K derived: sum of 2 quarters · filed 2026-08-06 | $132.00K 10-Q · filed 2025-11-06 | $184.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $85.00K 10-Q · filed 2026-08-06 | $137.00K derived: sum of 3 quarters · filed 2026-08-06 | $200.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $41.00K 10-Q · filed 2026-05-07 | $93.00K derived: sum of 2 quarters · filed 2026-05-07 | $156.00K derived: sum of 3 quarters · filed 2026-05-07 | $210.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $115.00K derived: sum of 2 quarters · filed 2026-02-26 | $169.00K derived: sum of 3 quarters · filed 2026-02-26 | $221.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $117.00K derived: sum of 2 quarters · filed 2025-11-06 | $169.00K 10-Q · filed 2025-11-06 | $219.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $106.00K 10-Q · filed 2025-08-07 | $156.00K derived: sum of 3 quarters · filed 2026-02-26 | $204.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $52.00K 10-Q · filed 2025-05-08 | $102.00K derived: sum of 2 quarters · filed 2026-02-26 | $150.00K derived: sum of 3 quarters · filed 2026-02-26 | $187.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $98.00K derived: sum of 2 quarters · filed 2026-02-26 | $135.00K derived: sum of 3 quarters · filed 2026-02-26 | $181.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $85.00K derived: sum of 2 quarters · filed 2024-11-07 | $131.00K 10-Q · filed 2024-11-07 | $135.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $83.00K 10-Q · filed 2024-08-08 | $87.00K derived: sum of 3 quarters · filed 2024-08-08 | $152.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $46.00K 10-Q · filed 2024-05-09 | $50.00K derived: sum of 2 quarters · filed 2024-05-09 | $115.00K derived: sum of 3 quarters · filed 2024-05-09 | $172.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $69.00K derived: sum of 2 quarters · filed 2024-02-22 | $126.00K derived: sum of 3 quarters · filed 2024-02-22 | $170.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | $65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $122.00K derived: sum of 2 quarters · filed 2023-11-09 | $166.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $101.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $44.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |